NBC News

Moderna’s mRNA flu vaccine more effective than standard shot in late-stage trial

The efficacy of flu shots is not always the same and it’s not always optimal. Some years, they can reduce the risk of illness by as little as 20% to 30%. Subscribe to read this story ad-free Get ...
The New York Times

Can This Start-Up Automate Home Maintenance?

Casa, a company founded by former Uber executives, says it uses artificial intelligence and a stable of handymen to take care of members’ homes. By Michael J. de la Merced Last year, Jessica Fain was ...
MarketWatch

Moderna’s stock rallies as settlement of a patent dispute clears vaccine pipeline

Shares of Moderna on Wednesday surged to their highest in more than a year after the pharmaceutical company said it reached a deal to resolve a dispute related to its COVID vaccine. Moderna MRNA said ...
STAT

Moderna’s reset hinges on oncology

Meghana Keshavan covers biotech and contributes to The Readout newsletter. Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
The News Journal

Moderna will pay up to $2.25B to end COVID vaccine patent fight

Moderna MRNA.O has agreed to pay Genevant Sciences, a subsidiary of Roivant Sciences ROIV.O, and Arbutus Biopharma ABUS.O up to $2.25 billion to settle a long-running legal fight over the technology ...
STAT

Moderna to pay Roivant up to $2.25 billion to settle patent lawsuit behind mRNA vaccines

Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77. This story has been updated. Moderna has ...
The Conversation

FDA’s abrupt flip‑flop on Moderna’s mRNA flu shot highlights growing risks to drug‑makers of investing in vaccines

The Food and Drug Administration’s decision, made public on Feb. 10, 2026, to not review an application to approve Moderna’s proposed mRNA-based flu vaccine set off a firestorm of criticism from ...
The Hill

FDA reverses course, will review Moderna’s mRNA flu vaccine candidate

The Food and Drug Administration (FDA) has backtracked its initial decision last week of refusing to review Moderna’s mRNA flu vaccine candidate after holding a high-priority meeting with the company.
WLWT

FDA reverses course and will review Moderna’s mRNA flu shot, company says

The U.S. Food and Drug Administration has reversed course and will review a new mRNA flu vaccine from Moderna, the pharmaceutical company said Wednesday.About two weeks ago, the FDA sent Moderna a ...
Seeking Alpha

Moderna dealt blows in ongoing patent dispute with Arbutus

A federal judge in Delaware has thrown out two key defenses Moderna (MRNA) had been claiming in its ongoing patent litigation with Arbutus Biopharma (ABUS) regarding its mRNA COVID-19 vaccine. Judge ...
New York Post

FDA reverses decision not to review Moderna’s new flu vaccine

The Food and Drug Administration has reversed its decision not to review a new flu vaccine from Moderna, the pharmaceutical company said Wednesday. Last week, the FDA sent a missive to Moderna ...